Nektar Therapeutics Shares Outstanding 2006-2020 | NKTR

Nektar Therapeutics shares outstanding from 2006 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Nektar Therapeutics Annual Shares Outstanding
(Millions of Shares)
2019 175
2018 180
2017 156
2016 140
2015 132
2014 127
2013 116
2012 115
2011 113
2010 94
2009 93
2008 92
2007 92
2006 90
2005 86
Nektar Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2020-09-30 179
2020-06-30 178
2020-03-31 177
2019-12-31 175
2019-09-30 175
2019-06-30 175
2019-03-31 174
2018-12-31 180
2018-09-30 173
2018-06-30 182
2018-03-31 161
2017-12-31 156
2017-09-30 163
2017-06-30 155
2017-03-31 154
2016-12-31 140
2016-09-30 137
2016-06-30 136
2016-03-31 136
2015-12-31 132
2015-09-30 133
2015-06-30 132
2015-03-31 136
2014-12-31 127
2014-09-30 132
2014-06-30 127
2014-03-31 124
2013-12-31 116
2013-09-30 116
2013-06-30 116
2013-03-31 115
2012-12-31 115
2012-09-30 115
2012-06-30 115
2012-03-31 115
2011-12-31 113
2011-09-30 114
2011-06-30 114
2011-03-31 109
2010-12-31 94
2010-09-30 94
2010-06-30 94
2010-03-31 94
2009-12-31 93
2009-09-30 93
2009-06-30 93
2009-03-31 93
2008-12-31 92
2008-09-30 92
2008-06-30 92
2008-03-31 92
2007-12-31 92
2007-09-30 92
2007-06-30 92
2007-03-31 91
2006-12-31 90
2006-09-30 90
2006-06-30 90
2006-03-31 89
2005-12-31 86
2005-09-30 86
2005-06-30 85
2005-03-31 85
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $3.089B $0.115B
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the company's wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $77.264B 42.12
Takeda Pharmaceutical (TAK) Japan $54.984B 10.26
Astellas Pharma (ALPMY) Japan $29.696B 18.55
Merck (MKGAF) Germany $23.264B 0.00
Eisai (ESALY) Japan $21.993B 19.16
UCB SA (UCBJF) Belgium $20.900B 0.00
Catalent (CTLT) United States $19.736B 59.03
Grifols, S.A (GRFS) Spain $13.600B 15.57
Neurocrine Biosciences (NBIX) United States $10.163B 79.99
Jazz Pharmaceuticals (JAZZ) Ireland $9.304B 15.03
Ionis Pharmaceuticals (IONS) United States $8.533B 83.60
Arrowhead Pharmaceuticals (ARWR) United States $8.441B 0.00
United Therapeutics (UTHR) United States $7.626B 16.24
IPSEN SA ADR (IPSEY) France $7.218B 0.00
STADA ARZNEIMI (STDAF) Germany $6.884B 0.00
Orion OYJ (ORINY) Finland $6.427B 22.30
Evotec AG (EVTCY) Germany $5.684B 385.28
Sage Therapeutics (SAGE) United States $4.661B 0.00
PTC Therapeutics (PTCT) United States $4.478B 0.00
ChemoCentryx (CCXI) United States $4.213B 0.00
Hypermarcas (HYPMY) Brazil $4.212B 16.63
FibroGen (FGEN) United States $4.006B 0.00
Cronos Group (CRON) Canada $3.946B 0.00
Corcept Therapeutics (CORT) United States $3.340B 32.30
Pacira BioSciences (PCRX) United States $3.208B 69.67
Revolution Medicines (RVMD) United States $2.852B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.851B 14.56
Xencor (XNCR) United States $2.842B 0.00
Tilray (TLRY) Canada $2.683B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.758B 15.04
USANA Health Sciences (USNA) United States $1.733B 15.25
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.725B 0.00
Translate Bio (TBIO) United States $1.708B 0.00
Heron Therapeutics (HRTX) United States $1.631B 0.00
Endo (ENDP) Ireland $1.626B 2.47
BioCryst Pharmaceuticals (BCRX) United States $1.601B 0.00
ImmunoGen (IMGN) United States $1.546B 0.00
Ocular Therapeutix (OCUL) United States $1.523B 0.00
Trillium Therapeutics (TRIL) Canada $1.494B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.448B 10.06
Indivior (INVVY) United States $1.309B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.182B 0.00
Karyopharm Therapeutics (KPTI) United States $1.110B 0.00
ORGANOGENESIS (ORGO) United States $1.023B 0.00
Zogenix (ZGNX) United States $1.017B 0.00
Radius Health (RDUS) United States $1.008B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.963B 0.00
CLINIGEN GP (CLIGF) United Kingdom $0.942B 0.00
Vectura Group (VEGPF) United Kingdom $0.925B 0.00
Collegium Pharmaceutical (COLL) United States $0.832B 49.10
Aclaris Therapeutics (ACRS) United States $0.808B 0.00
Calliditas Therapeutics AB (CALT) Sweden $0.770B 0.00
VAXART, INC (VXRT) United States $0.756B 0.00
Aerie Pharmaceuticals (AERI) United States $0.706B 0.00
Esperion Therapeutics (ESPR) United States $0.700B 0.00
Acutus Medical (AFIB) United States $0.658B 0.00
Chinook Therapeutics (KDNY) United States $0.640B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.637B 0.00
Ardelyx (ARDX) United States $0.616B 0.00
Harpoon Therapeutics (HARP) United States $0.613B 0.00
Flexion Therapeutics (FLXN) United States $0.590B 0.00
Molecular Templates (MTEM) United States $0.589B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.581B 0.00
Siga Technologies (SIGA) United States $0.557B 15.63
Crinetics Pharmaceuticals (CRNX) United States $0.497B 0.00
Sundial Growers (SNDL) Canada $0.488B 0.00
PROFOUND MEDICL (PROF) Canada $0.465B 0.00
Akebia Therapeutics (AKBA) United States $0.454B 0.00
Altimmune (ALT) United States $0.449B 0.00
Summit Therapeutics (SMMT) United States $0.431B 0.00
CASI Pharmaceuticals (CASI) United States $0.429B 0.00
TherapeuticsMD (TXMD) United States $0.426B 0.00
DURECT (DRRX) United States $0.423B 0.00
Rafael Holdings (RFL) United States $0.396B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.394B 0.00
Jounce Therapeutics (JNCE) United States $0.384B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.371B 9.68
Innate Pharma SA (IPHYF) France $0.371B 0.00
MEI Pharma (MEIP) United States $0.347B 0.00
Concert Pharmaceuticals (CNCE) United States $0.334B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.329B 0.00
Alpine Immune Sciences (ALPN) United States $0.312B 0.00
Nature's Sunshine Products (NATR) United States $0.306B 19.73
KalVista Pharmaceuticals (KALV) United States $0.305B 0.00
Menlo Therapeutics (VYNE) United States $0.299B 0.00
Redhill Biopharma (RDHL) Israel $0.291B 0.00
Lannett Co Inc (LCI) United States $0.281B 7.41
Xeris Pharmaceuticals (XERS) United States $0.275B 0.00
Jaguar Animal Health (JAGX) United States $0.263B 0.00
Otonomy (OTIC) United States $0.250B 0.00
IMV INC (IMV) Canada $0.248B 0.00
CTI BioPharma (CTIC) United States $0.239B 0.00
Oncternal Therapeutics (ONCT) United States $0.226B 0.00
Infinity Pharmaceuticals (INFI) United States $0.223B 0.00
Calithera Biosciences (CALA) United States $0.219B 0.00
OptiNose (OPTN) United States $0.215B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.213B 0.00
IsoRay (ISR) United States $0.210B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.205B 0.00
Novan (NOVN) United States $0.185B 0.00
Aquestive Therapeutics (AQST) United States $0.183B 0.00
Ayala Pharmaceuticals (AYLA) Israel $0.176B 0.00
Taiwan Liposome (TLC) Taiwan $0.172B 0.00
Onconova Therapeutics (ONTX) United States $0.161B 0.00
Heat Biologics (HTBX) United States $0.157B 0.00
Champions Oncology (CSBR) United States $0.154B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.153B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.148B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.145B 0.00
ProPhase Labs (PRPH) United States $0.145B 0.00
MediWound (MDWD) Israel $0.144B 0.00
Lipocine (LPCN) United States $0.116B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.108B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.105B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.099B 0.00
ElectroCore (ECOR) United States $0.086B 0.00
Hemispherx BioPharma (AIM) United States $0.085B 0.00
SCYNEXIS (SCYX) United States $0.085B 0.00
Natural Alternatives (NAII) United States $0.083B 161.13
Galmed Pharmaceuticals (GLMD) Israel $0.079B 0.00
Nutriband (NTRB) United States $0.077B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.072B 0.00
Biomerica (BMRA) United States $0.072B 0.00
Recro Pharma (REPH) United States $0.072B 0.00
AgeX Therapeutics (AGE) United States $0.071B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.069B 0.00
India Globalization Capital (IGC) United States $0.066B 0.00
Iterum Therapeutics (ITRM) Ireland $0.064B 0.00
CV Sciences (CVSI) United States $0.061B 0.00
Vical (BBI) United States $0.060B 0.00
Addex Therapeutics (ADXN) Switzerland $0.058B 0.00
RENEURON GP (RNUGF) United Kingdom $0.053B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.053B 0.00
Trimel Pharmaceuticals (ASPCF) Canada $0.051B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.048B 24.58
Regulus Therapeutics (RGLS) United States $0.045B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.043B 0.00
PolarityTE (PTE) United States $0.042B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.040B 0.00
Mannatechorporated (MTEX) United States $0.039B 5.74
Neos Therapeutics (NEOS) United States $0.037B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.030B 0.00
Midatech Pharma (MTP) United Kingdom $0.029B 0.00
Flex Pharma (SLRX) United States $0.029B 0.00
Can-Fite Biopharma (CANF) Israel $0.029B 0.00
KemPharm (KMPH) United States $0.026B 0.00
China SXT Pharmaceuticals (SXTC) China $0.021B 0.00
HANCOCK JAFFE (HJLI) United States $0.020B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.020B 0.00
Cyanotech (CYAN) United States $0.019B 31.90
Xenetic Biosciences (XBIO) United States $0.017B 0.00
RXi Pharmaceuticals (PHIO) United States $0.017B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.017B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.011B 0.00
Shineco (TYHT) China $0.011B 0.00
JanOne (JAN) United States $0.010B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00